Skip to content

US · BBIO · BIOTECHNOLOGY

BridgeBio Pharma, Inc. (BBIO) intrinsic value and stock valuation

$76.03as of 2026-11-21 · Mkt cap 16.06B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BridgeBio Pharma, Inc. DCF and intrinsic value

InvestorsCraft values BBIO with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from BBIO’s statements →

BridgeBio Pharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Palo Alto, CA 94304 bridgebio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$502.1M+127.4% 5y CAGRd
20172025
Net income
-$-729.31M
20172025
Free cash flow
-$-447.01M
20172025
Total equity
-$-2.08B
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$502.1M$221.9M$9.3M$77.7M$69.7M
Operating income-$-569.09M-$-592.97M-$-607.37M-$-512.2M-$-576.63M
Net income-$-729.31M-$-535.76M-$-643.2M-$-481.18M-$-562.54M
EPSd-$-3.7M-$-2.88M-$-3.95M-$-3.26M-$-3.9M
Operating cash flow-$-445.91M-$-520.73M-$-527.72M-$-419.49M-$-497.93M
Capital expenditure-$-1.1M-$-930K-$-1.31M-$-6.32M-$-48.25M
Free cash flow-$-447.01M-$-521.66M-$-529.03M-$-425.81M-$-546.18M
Total assets$936M$919.3M$546.4M$623M$1.01B
Total debt$2.73B$1.73B$1.74B$1.72B$1.73B
Net debt$2.16B$1.05B$1.36B$1.35B$1.33B
Total equity-$-2.08B-$-1.46B-$-1.34B-$-1.24B-$-865.58M
Cash and short-term investments$587.5M$681.1M$434.9M$471.9M$836.7M
Income statement
20252024202320222021
Revenue$502.1M$221.9M$9.3M$77.7M$69.7M
Cost of revenue$28.3M$3.88M$2.45M$3.43M$3.11M
Gross profit$473.8M$218M$6.86M$74.2M$66.6M
Research and development expenses$477.5M$506.5M$455.7M$399.5M$451M
Selling, general and administrative expenses$555.1M$288.9M$150.6M$143.2M$192.2M
Other expenses$10.2M$15.6M$7.93M$43.8M$0.00
Operating expenses$1.04B$811M$614.2M$586.4M$643.2M
Cost and expenses$1.07B$814.9M$616.7M$589.9M$646.4M
Interest income$19.9M$17.3M$18M$7.54M$1.13M
Interest expense$53.1M$99.3M$81.3M$80.4M$46.8M
Depreciation and amortization$9M$6.08M$6.49M$6.77M$5.84M
Ebitda-$-672.88M-$-436.83M-$-565.47M-$-397.44M-$-533.83M
Operating income-$-569.09M-$-592.97M-$-607.37M-$-512.2M-$-576.63M
Total other income/expenses, net-$-165.9M$50.8M-$-45.88M$27.6M-$-9.82M
Income before tax-$-734.99M-$-542.19M-$-653.25M-$-484.65M-$-586.45M
Income tax expense$560K$1.15M$0.00$0.00$0.00
Net income-$-729.31M-$-535.76M-$-643.2M-$-481.18M-$-562.54M
Weighted average shares outstanding$197.2M$186.1M$162.8M$147.5M$144.4M
Weighted average diluted shares outstanding$197.2M$186.1M$162.8M$147.5M$144.4M
Balance sheet
20252024202320222021
Cash and short-term investments$587.5M$681.1M$434.9M$471.9M$836.7M
Net receivables$139.4M$4.72M$1.75M$17.1M$19.8M
Inventory$26.8M$0.00$0.00$0.00$0.00
Total current assets$753.7M$720.7M$477.6M$548.9M$888.9M
Property, plant and equipment, net$13.5M$12.8M$19.8M$25.3M$46M
Goodwill and intangible assets$28.1M$23.9M$26.3M$28.7M$44.9M
Long-term investments$81.4M$143.8M$3.74M$2.87M$2.42M
Total non-current assets$41.6M$198.7M$68.8M$74.2M$123.9M
Total assets$936M$919.3M$546.4M$623M$1.01B
Accounts payable$36.2M$9.62M$10.7M$11.6M$11.9M
Short-term debt$17.4M$4.51M$4.13M$3.67M$4.94M
Deferred revenue$20.3M$0.00$6.1M$8.16M$0.00
Total current liabilities$288M$154.4M$143.8M$121.4M$135.1M
Long-term debt$2.71B$1.73B$1.74B$1.72B$1.72B
Deferred revenue, non-current$13.1M$0.00$0.00$0.00$0.00
Total non-current liabilities$2.72B$2.22B$1.75B$1.75B$1.74B
Capital lease obligations$3.81M$9.2M$13.1M$16M$22.4M
Total liabilities$3.01B$2.38B$1.89B$1.87B$1.88B
Common stock$200K$200K$180K$160K$150K
Retained earnings-$-3.82B-$-3.1B-$-2.56B-$-1.92B-$-1.44B
Accumulated other comprehensive income (loss)$10K$10K$30K-$-330K-$-130K
Total equity-$-2.08B-$-1.46B-$-1.34B-$-1.24B-$-865.58M
Total investments$98.8M$143.8M$62.7M$98.1M$445.3M
Total debt$2.73B$1.73B$1.74B$1.72B$1.73B
Net debt$2.16B$1.05B$1.36B$1.35B$1.33B
Cash flow statement
20252024202320222021
Net income-$-724.93M-$-543.35M-$-643.2M-$-484.65M-$-586.45M
Depreciation and amortization$5.97M$6.08M$6.49M$6.77M$5.84M
Stock-based compensation$133M$95.8M$0.00$91.6M$99.5M
Change in working capital-$-51.06M$32M$5.06M$28.1M-$-4.4M
Accounts receivable-$-134.72M-$-2.97M$15.3M$15.2M-$-19.75M
Inventory-$-25.31M$0.00$0.00$0.00$19.8M
Accounts payable$26.6M$1.51M$2.78M-$-350K$2.83M
Net cash provided by operating activities-$-445.91M-$-520.73M-$-527.72M-$-419.49M-$-497.93M
Investments in property, plant and equipment-$-1.1M-$-930K-$-1.31M-$-4.82M-$-48.25M
Acquisitions, net$0.00-$-140K$0.00$0.00-$-35M
Net cash used for investing activities-$-24.49M$60.8M$54M$453.2M-$-200.83M
Common stock issued$34.2M$314.7M$449.8M$4.85M$0.00
Common stock repurchased-$-48.28M-$-7.53M-$-6.88M-$-1.56M-$-204.75M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$359.3M$748.5M$451.5M-$-13.13M$736.5M
Net change in cash-$-111.1M$288.5M-$-22.15M$20.5M$37.7M
Cash at end of period$572.1M$683.2M$394.7M$416.9M$396.4M
Operating cash flow-$-445.91M-$-520.73M-$-527.72M-$-419.49M-$-497.93M
Capital expenditure-$-1.1M-$-930K-$-1.31M-$-6.32M-$-48.25M
Free cash flow-$-447.01M-$-521.66M-$-529.03M-$-425.81M-$-546.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BridgeBio Pharma, Inc.

        BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

        CEO
        Neil Kumar
        Employees
        839
        Beta
        0.95

        Explore

        Frequently asked questions

        What is the intrinsic value of BridgeBio Pharma, Inc. (BBIO)?

        BridgeBio Pharma, Inc. (BBIO) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BBIO undervalued?

        BBIO trades at a price of $76.03 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.